dendritic vaccine pulsed with glioma peptides
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 14, 2005 (NCT00108264)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dendritic cells with peptides for recurrent malignant gliomas
- dendritic vaccine pulsed with glioma peptides
- glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
- tumor rna transfected dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00766753 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2006 | Oncovir, Inc., University of Pittsburgh |
| NCT00612001 | Phase 1 | May 1, 2006 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00108264 | Phase 1 | Apr 14, 2005 | Department of Veteran Affairs |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2006 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2006 |
5 organizations
Page 1 / 1